ENZON PHARMACEUTICALS INC
ENZN
ENZN was delisted on the 19th of May, 2016.
1 hedge funds and large institutions have $10K invested in ENZON PHARMACEUTICALS INC in 2017 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
47% less capital invested
Capital invested by funds: $19K → $10K (-$9K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$2.23K |
ENZN Hedge Fund Activity: Q3 2017 in Review
1 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in ENZON PHARMACEUTICALS INC (ENZN) for Q3 2017, worth a combined $10K — down 47% from $19K a quarter earlier.
Fund positioning in ENZN was balanced in Q3 2017: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was Panagora Asset Management, cutting an estimated $2.23K.
- 1 institutional investor held ENZON PHARMACEUTICALS INC (ENZN) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $10K of ENZON PHARMACEUTICALS INC stock for Q3 2017, down 47% quarter-over-quarter.
- 0 funds opened new ENZON PHARMACEUTICALS INC positions in Q3 2017 and 0 closed out.
- The largest ENZON PHARMACEUTICALS INC seller in Q3 2017 was Panagora Asset Management, an estimated $2.23K sold.
Based on aggregated 13F filings for Q3 2017.